Akash Tewari
Stock Analyst at Jefferies
(4.76)
# 626
Out of 4,996 analysts
501
Total ratings
58.9%
Success rate
12.9%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Reiterated: Buy | $78 → $83 | $43.29 | +91.73% | 30 | Sep 22, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,440 | $1,170.14 | +23.06% | 47 | Sep 22, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $138 | $100.87 | +36.81% | 40 | Sep 15, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $98 → $126 | $91.97 | +37.00% | 6 | Sep 9, 2026 | |
| LTGO Latigo Biotherapeutics | Initiated Coverage: Buy | $50 | $20.82 | +140.15% | 1 | Sep 1, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $104 → $105 | $63.37 | +65.69% | 39 | Aug 31, 2026 | |
| DMRA Damora Therapeutics | Reiterated: Buy | $50 | $22.41 | +123.11% | 2 | Aug 11, 2026 | |
| JBIO Jade Biosciences | Reiterated: Buy | $40 → $48 | $16.76 | +186.40% | 3 | Aug 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $610 → $633 | $514.99 | +22.92% | 4 | Aug 11, 2026 | |
| PFE Pfizer | Reiterated: Buy | $34 | $27.93 | +21.73% | 45 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $142.25 | +40.60% | 29 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $45.75 | +96.72% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180 | $152.67 | +17.90% | 2 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.31 | +322.96% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $885 → $890 | $803.90 | +10.71% | 35 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $410.24 | -14.68% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $980 → $1,008 | $963.79 | +4.59% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $46 | $58.15 | -20.89% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $35 | $16.44 | +112.90% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $42 | $27.57 | +52.37% | 6 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $12.42 | +61.03% | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $67.59 | n/a | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $398 → $502 | $518.83 | n/a | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $150.91 | n/a | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $8.51 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $68 | $62.25 | n/a | 13 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $183 | $240.57 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $2.5 | $3.08 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $19.35 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $2.15 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.18 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.17 | n/a | 2 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9 | $39.52 | n/a | 1 | Jul 19, 2019 |
Alkermes
Sep 22, 2026
Reiterated: Buy
Price Target: $78 → $83
Current: $43.29
Upside: +91.73%
Eli Lilly and Company
Sep 22, 2026
Reiterated: Buy
Price Target: $1,440
Current: $1,170.14
Upside: +23.06%
BioNTech SE
Sep 15, 2026
Reiterated: Buy
Price Target: $138
Current: $100.87
Upside: +36.81%
Spyre Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $98 → $126
Current: $91.97
Upside: +37.00%
Latigo Biotherapeutics
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $20.82
Upside: +140.15%
BioMarin Pharmaceutical
Aug 31, 2026
Reiterated: Buy
Price Target: $104 → $105
Current: $63.37
Upside: +65.69%
Damora Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $50
Current: $22.41
Upside: +123.11%
Jade Biosciences
Aug 11, 2026
Reiterated: Buy
Price Target: $40 → $48
Current: $16.76
Upside: +186.40%
Vertex Pharmaceuticals
Aug 11, 2026
Reiterated: Buy
Price Target: $610 → $633
Current: $514.99
Upside: +22.92%
Pfizer
Aug 5, 2026
Reiterated: Buy
Price Target: $34
Current: $27.93
Upside: +21.73%
Jul 30, 2026
Reiterated: Buy
Price Target: $200
Current: $142.25
Upside: +40.60%
Jul 15, 2026
Reiterated: Buy
Price Target: $90
Current: $45.75
Upside: +96.72%
May 22, 2026
Reiterated: Buy
Price Target: $180
Current: $152.67
Upside: +17.90%
Apr 30, 2026
Reiterated: Buy
Price Target: $14
Current: $3.31
Upside: +322.96%
Mar 11, 2026
Reiterated: Buy
Price Target: $885 → $890
Current: $803.90
Upside: +10.71%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $410.24
Upside: -14.68%
Feb 19, 2026
Reiterated: Buy
Price Target: $980 → $1,008
Current: $963.79
Upside: +4.59%
Dec 11, 2025
Reiterated: Buy
Price Target: $50 → $46
Current: $58.15
Upside: -20.89%
Dec 5, 2025
Reiterated: Buy
Price Target: $26 → $35
Current: $16.44
Upside: +112.90%
Nov 17, 2025
Reiterated: Buy
Price Target: $13 → $42
Current: $27.57
Upside: +52.37%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $12.42
Upside: +61.03%
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $67.59
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $398 → $502
Current: $518.83
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $138
Current: $150.91
Upside: n/a
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $8.51
Upside: n/a
Apr 23, 2025
Reiterated: Buy
Price Target: $70 → $68
Current: $62.25
Upside: n/a
Apr 1, 2025
Reiterated: Buy
Price Target: $183
Current: $240.57
Upside: n/a
Jan 29, 2025
Reiterated: Hold
Price Target: $6 → $2.5
Current: $3.08
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $19.35
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $2.15
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $17.18
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $8.17
Upside: n/a
Jul 19, 2019
Initiated Coverage: Hold
Price Target: $9
Current: $39.52
Upside: n/a